{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:25:01Z","timestamp":1790717101626,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005410","name":"American-Italian Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005410","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ejca.2025.115739","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T20:54:49Z","timestamp":1755809689000},"page":"115739","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Positioning oral selective estrogen receptor degraders in patients with metastatic breast cancer"],"prefix":"10.1016","volume":"228","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1150-0345","authenticated-orcid":false,"given":"Carmine","family":"Valenza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1781-2518","authenticated-orcid":false,"given":"Giuseppe","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2025.115739_bib1","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/S0140-6736(20)32381-3","article-title":"Breast cancer","volume":"397","author":"Loibl","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2025.115739_bib2","doi-asserted-by":"crossref","first-page":"4594","DOI":"10.1200\/JCO.2010.28.8415","article-title":"Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen Receptor\u2013Positive advanced breast cancer","volume":"28","author":"Di Leo","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115739_bib3","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1200\/JCO.22.00338","article-title":"Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen Receptor\u2013Positive, human epidermal growth factor receptor 2\u2013Negative advanced breast cancer: results from the randomized phase III EMERALD trial","volume":"40","author":"Bidard","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115739_bib4","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/S1470-2045(24)00387-5","article-title":"Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial","volume":"25","author":"Oliveira","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2025.115739_bib5","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa2410858","article-title":"Imlunestrant with or without abemaciclib in advanced breast cancer","volume":"392","author":"Jhaveri","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.115739_bib6","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1200\/JCO.22.02746","article-title":"AMEERA-3: randomized phase II study of amcenestrant (Oral Selective Estrogen Receptor Degrader) versus standard endocrine monotherapy in estrogen Receptor\u2013Positive, human epidermal growth factor receptor 2\u2013Negative advanced breast cancer","volume":"41","author":"Tolaney","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115739_bib7","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1200\/JCO.23.01500","article-title":"Giredestrant for estrogen Receptor\u2013Positive, HER2-Negative, previously treated advanced breast cancer: results from the randomized, phase II acelERA breast cancer study","volume":"42","author":"Mart\u00edn","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115739_bib8","doi-asserted-by":"crossref","first-page":"TPS1119","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS1119","article-title":"evERA breast cancer (BC): phase III study of giredestrant + everolimus vs exemestane + everolimus in patients (pts) with estrogen receptor-positive, HER2-negative locally advanced or metastatic BC (ER+, HER2\u2013 LA\/mBC)","volume":"41","author":"Mayer","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115739_bib9","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1016\/S0140-6736(16)32389-3","article-title":"Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial","volume":"388","author":"Robertson","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2025.115739_bib10","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1056\/NEJMoa1811714","article-title":"Overall survival with fulvestrant plus anastrozole in metastatic breast cancer","volume":"380","author":"Mehta","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.115739_bib11","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1200\/JCO.24.00994","article-title":"Fulvestrant versus anastrozole in endocrine Therapy\u2013Na\u00efve women with hormone Receptor\u2013Positive advanced breast cancer: final overall survival in the phase III FALCON trial","volume":"43","author":"Robertson","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115739_bib12","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1056\/NEJMoa1201622","article-title":"Combination anastrozole and fulvestrant in metastatic breast cancer","volume":"367","author":"Mehta","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.115739_bib13","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1200\/JCO.23.02036","article-title":"Randomized phase III study of amcenestrant plus palbociclib versus letrozole plus palbociclib in estrogen Receptor\u2013Positive, human epidermal growth factor receptor 2\u2013Negative advanced breast cancer: primary results from AMEERA-5","volume":"42","author":"Cort\u00e9s","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115739_bib14","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1001\/jamaoncol.2021.4301","article-title":"Fulvestrant-Palbociclib vs Letrozole-Palbociclib as initial therapy for Endocrine-Sensitive, hormone Receptor\u2013Positive, erbb2 -Negative advanced breast cancer","volume":"7","author":"Llombart-Cussac","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2025.115739_bib15","doi-asserted-by":"crossref","first-page":"TPS1101","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS1101","article-title":"SERENA-4: a phase 3 comparison of AZD9833 (camizestrant) plus palbociclib, versus anastrozole plus palbociclib, for patients with ER-positive, HER2-negative advanced breast cancer who have not previously received systemic treatment for advanced disease","volume":"39","author":"Im","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115739_bib16","doi-asserted-by":"crossref","first-page":"TPS1103","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS1103","volume":"39","author":"Turner","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115739_bib17","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S1470-2045(22)00555-1","article-title":"Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial","volume":"23","author":"Bidard","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2025.115739_bib18","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1200\/JCO.2023.41.16_suppl.1002","article-title":"Dynamics and type of esr1 mutations under aromatase inhibitor or fulvestrant combined with palbociclib after randomization in the PADA-1 trial","volume":"41","author":"Cabel","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115739_bib19","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2502929","article-title":"First-Line camizestrant for emerging esr1 -Mutated advanced breast cancer","author":"Bidard","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.115739_bib20","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(10)61268-8","article-title":"Early versus delayed treatment of relapsed ovarian cancer (MRC OV05\/EORTC 55955): a randomised trial","volume":"376","author":"Rustin","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2025.115739_bib21","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.1200\/JCO.2014.56.2561","article-title":"Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500","volume":"32","author":"Smerage","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115739_bib22","article-title":"Factors associated with first-to-second-line attrition among patients with metastatic breast cancer in the real world","volume":"10","author":"Blondeaux","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2025.115739_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.soncn.2023.151502","article-title":"Scan-Associated distress in people affected by cancer: a qualitative systematic review","volume":"39","author":"Hussain","year":"2023","journal-title":"Semin Oncol Nurs"},{"key":"10.1016\/j.ejca.2025.115739_bib24","unstructured":"Cifuentes Canaval S. SERENA-6 \u2013 Unpacking the Economic Reality of ESR1m Surveillance in Breast Cancer. Https:\/\/OncodailyCom\/ 2025."}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925005222?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925005222?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T09:46:00Z","timestamp":1779702360000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925005222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":24,"alternative-id":["S0959804925005222"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115739","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Positioning oral selective estrogen receptor degraders in patients with metastatic breast cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115739","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115739"}}